Le Lézard
Classified in: Environment, Health, Science and technology
Subjects: PDT, SVY, CSR

Angel Yeast Publishes 2023 Corporate Social Responsibility Report


SHANGHAI, April 29, 2024 /PRNewswire/ -- Angel Yeast, (SH600298), the world's leading yeast manufacturer, has released its 2023 CSR Report (the "Report"). The Report highlights the company's mission and vision, advancements in international expansion, intelligent and digital strategies, patent development, social responsibility efforts, and initiatives for employee growth and development.

Angel Yeast Publishes 2023 Corporate Social Responsibility Report

The Report details Angel Yeast's pursuit of balanced and harmonious development with the employees, society, and nature, and its unremitting efforts to fulfill social responsibilities and giving back to society with concrete actions.

Leading sustainable development to build a greener future

In 2023, Angel Yeast continued to promote cleaner production and lowered all energy consumption and pollutant emission indicators ? its comprehensive energy consumption per unit of product has decreased by 0.9 percent year-on-year, while cutting 190,100 tons of carbon through various actions.

The group has increased investment into environmental protection and optimized existing treatment facilities, with the full installation of energy-saving equipment and implementation of energy conservation technologies, as well as waste heat and pressure recovery, it has achieved energy-saving and carbon reduction goals.

Angel Yeast is actively monitoring its environmental impact by employing manual lab testing, commissioned monitoring, and online methods to track wastewater, exhaust gas, and noise emissions.

The company places a high priority on employee safety and well-being, conducting 1,623 safety training sessions for 104,481 attendees and 609 emergency drills involving 22,313 participants in 2023. Additionally, Angel Yeast is committed to social welfare, demonstrated by passing the ECOVADIS social responsibility accreditation in December 2023.

Promoting a healthy lifestyle with technology and innovation

In 2023, Angel Yeast invested 603 million yuan (USD 83.31 million) in R&D, marking a 12.5% increase from the previous year. The company applied for 1,367 patents across various fields, holding 159 valid invention patents in China and 106 overseas, alongside 180 utility models and 58 design patents.

 Technological advancements in yeast strain selection, high-efficiency fermentation, and complex enzymatic digestion enabled a 20% reduction in salt usage. "We cannot grow the company without social responsibility. Angel Yeast will continue to uphold the mission to develop biotechnology and innovate through delivering high-quality products and services, creating greater values for our customers, and giving back to society through public welfare programs," said Xiao Minghua GM of Angel Yeast.

For more information, please visit: https://en.angelyeast.com/upload/files/2024/2023-angel-yeast-csr-report.pdf

Photo - https://mma.prnewswire.com/media/2399406/20240428152212.jpg
Logo - https://mma.prnewswire.com/media/1586948/angel_logo_Logo.jpg


These press releases may also interest you

at 19:35
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for...

at 19:34
Andlauer Healthcare Group Inc. ("AHG" or the "Company") today announced that the Board has approved a substantial issuer bid (the "Offer") under which the Company will offer to purchase for cancellation up to 2,000,000 subordinate voting shares of...

at 19:30
The global electrophysiology market  size is estimated to grow by USD 6.09 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  10.71%  during the forecast period. ...

at 18:45
Kerecis, the pioneer in the use of fish skin and fatty acids for tissue regeneration and protection, will unveil its latest scientific and clinical updates, including trial results, at the upcoming Symposium on Advanced Wound Care (SAWC) Spring. The...

at 18:38
Actinium Pharmaceuticals, Inc. ...

at 18:26
StretchMed, a leading innovator in the health & wellness industry, is thrilled to announce its upcoming Regulation Crowdfunding (REG CF) raise in partnership with Republic, the prominent investment platform democratizing access to investments in...



News published on and distributed by: